Comprehensive analysis of germline drivers in endometrial cancer.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
received:
11
10
2022
revised:
12
12
2022
accepted:
23
01
2023
pmc-release:
06
02
2024
medline:
9
5
2023
pubmed:
7
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
We sought to determine the prevalence of germline pathogenic variants (gPVs) in unselected patients with endometrial cancer (EC), define biallelic gPVs within tumors, and describe their associations with clinicopathologic features. Germline assessment of at least 76 cancer predisposition genes was performed in patients with EC undergoing clinical tumor-normal Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing from January 1, 2015, to June 30, 2021. In patients with gPVs, biallelic alterations in ECs were identified through analysis of loss of heterozygosity and somatic PVs. Clinicopathologic variables were compared using nonparametric tests. Of 1625 patients with EC, 216 (13%) had gPVs, and 15 patients had 2 gPVs. There were 231 gPVs in 35 genes (75 [32%] high penetrance; 39 [17%] moderate penetrance; and 117 [51%] low, recessive, or uncertain penetrance). Compared with those without gPVs, patients with gPVs were younger (P = .002), more often White (P = .009), and less obese (P = .025) and had differences in distribution of tumor histology (P = .017) and molecular subtype (P < .001). Among 231 gPVs, 74 (32%) exhibited biallelic inactivation within tumors. For high-penetrance gPVs, 63% (47 of 75) of ECs had biallelic alterations, primarily affecting mismatch repair (MMR) and homologous recombination related genes, including BRCA1,BRCA2, RAD51D, and PALB2. Biallelic inactivation varied across molecular subtypes with highest rates in microsatellite instability-high (MSI-H) or copy-number (CN)-high subtypes (3 of 12 [25%] POLE, 30 of 77 [39%] MSI-H, 27 of 60 [45%] CN-high, 9 of 57 [16%] CN-low; P < .001). Of unselected patients with EC, 13% had gPVs, with 63% of gPVs in high-penetrance genes (MMR and homologous recombination) exhibiting biallelic inactivation, potentially driving cancer development. This supports germline assessment in EC given implications for treatment and cancer prevention.
Sections du résumé
BACKGROUND
We sought to determine the prevalence of germline pathogenic variants (gPVs) in unselected patients with endometrial cancer (EC), define biallelic gPVs within tumors, and describe their associations with clinicopathologic features.
METHODS
Germline assessment of at least 76 cancer predisposition genes was performed in patients with EC undergoing clinical tumor-normal Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing from January 1, 2015, to June 30, 2021. In patients with gPVs, biallelic alterations in ECs were identified through analysis of loss of heterozygosity and somatic PVs. Clinicopathologic variables were compared using nonparametric tests.
RESULTS
Of 1625 patients with EC, 216 (13%) had gPVs, and 15 patients had 2 gPVs. There were 231 gPVs in 35 genes (75 [32%] high penetrance; 39 [17%] moderate penetrance; and 117 [51%] low, recessive, or uncertain penetrance). Compared with those without gPVs, patients with gPVs were younger (P = .002), more often White (P = .009), and less obese (P = .025) and had differences in distribution of tumor histology (P = .017) and molecular subtype (P < .001). Among 231 gPVs, 74 (32%) exhibited biallelic inactivation within tumors. For high-penetrance gPVs, 63% (47 of 75) of ECs had biallelic alterations, primarily affecting mismatch repair (MMR) and homologous recombination related genes, including BRCA1,BRCA2, RAD51D, and PALB2. Biallelic inactivation varied across molecular subtypes with highest rates in microsatellite instability-high (MSI-H) or copy-number (CN)-high subtypes (3 of 12 [25%] POLE, 30 of 77 [39%] MSI-H, 27 of 60 [45%] CN-high, 9 of 57 [16%] CN-low; P < .001).
CONCLUSIONS
Of unselected patients with EC, 13% had gPVs, with 63% of gPVs in high-penetrance genes (MMR and homologous recombination) exhibiting biallelic inactivation, potentially driving cancer development. This supports germline assessment in EC given implications for treatment and cancer prevention.
Identifiants
pubmed: 36744932
pii: 7028492
doi: 10.1093/jnci/djad016
pmc: PMC10165491
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-569Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
JCO Precis Oncol. 2019;3:
pubmed: 32775946
JAMA Oncol. 2022 Jun 1;8(6):895-903
pubmed: 35511145
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Genet Med. 2016 Apr;18(4):325-32
pubmed: 26133394
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
JCO Precis Oncol. 2021 Nov;5:1588-1602
pubmed: 34994648
Cancer. 2019 Sep 15;125(18):3172-3183
pubmed: 31150123
Genet Med. 2022 Jun;24(6):1187-1195
pubmed: 35346574
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Gynecol Oncol. 2022 Jun;165(3):546-551
pubmed: 35483985
J Med Genet. 2000 Nov;37(11):828-30
pubmed: 11073535
Gynecol Oncol. 2021 Oct;163(1):14-21
pubmed: 34446268
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Nat Rev Clin Oncol. 2016 Sep;13(9):581-8
pubmed: 27296296
Mod Pathol. 2022 Sep;35(9):1269-1278
pubmed: 35365770
BMC Med Genomics. 2017 May 19;10(1):33
pubmed: 28526081
Nat Commun. 2015 Dec 22;6:10086
pubmed: 26689913
Mod Pathol. 2016 Nov;29(11):1381-1389
pubmed: 27443514
J Med Genet. 2004 May;41(5):323-6
pubmed: 15121767
JCO Precis Oncol. 2019 Aug 29;3:
pubmed: 32914019
J Clin Oncol. 2021 Aug 20;39(24):2698-2709
pubmed: 34133209
J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211
pubmed: 33710348
Cancer Res. 2006 Aug 1;66(15):7810-7
pubmed: 16885385
Genet Med. 2020 Dec;22(12):2089-2100
pubmed: 32792570
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Clin Cancer Res. 2021 May 1;27(9):2613-2623
pubmed: 33602681
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
JAMA Oncol. 2016 Nov 01;2(11):1434-1440
pubmed: 27367496
Int J Cancer. 2016 Oct 1;139(7):1557-63
pubmed: 27194394
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Nat Genet. 1996 May;13(1):114-6
pubmed: 8673088
Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):362-371
pubmed: 34810208
Clin Cancer Res. 2022 Oct 3;28(19):4302-4311
pubmed: 35849120
Nat Commun. 2017 Oct 11;8(1):857
pubmed: 29021619
Sci Rep. 2021 Jun 18;11(1):12880
pubmed: 34145315
J Clin Oncol. 2020 May 1;38(13):1398-1408
pubmed: 31922925
Gynecol Oncol. 2022 Aug;166(2):344-350
pubmed: 35691755
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Cancer. 2013 Jan 15;119(2):332-8
pubmed: 22811390
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Obstet Gynecol. 2022 Apr 1;139(4):645-659
pubmed: 35272301
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821